The effect of NBS powder in treatment of patients with COVID-19

Evaluation of the effect of Nutrition Bio-Safety (NBS) powder on immune system function and clinical manifestations in patients with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200426047206N1

Enrollment

Registered

2020-04-28

Start date

2020-05-09

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia. COVID-19,

Interventions

Intervention 1: Intervention group: Patients in intervention group in addition to the standard antiviral treatment of the two-drug regimen, NBS powder will be prescribe is below: Dosage of NBS is 500

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Covid 19 positive patients with with age over 20 years

Exclusion criteria

Exclusion criteria: Disagreement of the patient or relatives to participate in the project Drug sensitivity to NBS Patient death during common and selective treatments

Design outcomes

Primary

Measure	Time frame
Pulmonary symptoms. Timepoint: 4 weeks after intervention. Method of measurement: CT Scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarid Azizi Jalilian

Hamedan University of Medical Sciences

azizifarid@gmail.com+98 81 3838 0717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 11, 2026